Late mortality from pT1N0M0 breast carcinoma

Area of Science:

• Oncology
• Pathology
• Epidemiology

Background:

• pT1N0M0 breast carcinoma, defined as tumors ≤ 2 cm with negative lymph nodes, generally has favorable survival rates.
• Limited data exist on the very long-term outcomes for patients diagnosed with this early-stage breast cancer.
• Understanding long-term prognosis is crucial for patient counseling and treatment planning.

Purpose of the Study:

• To evaluate the long-term survival and mortality patterns of patients with pT1N0M0 breast carcinoma.
• To identify prognostic factors influencing long-term outcomes in this patient cohort.
• To assess the impact of tumor differentiation and size on breast cancer-specific survival.

Main Methods:

• A population-based cohort of 265 women with unilateral pT1N0M0 breast carcinoma diagnosed between 1945-1984 was identified.
• Patients underwent mastectomy and axillary lymph node dissection without adjuvant systemic therapy.
• Follow-up extended for 10-44 years (median 17 years), including clinical and autopsy data review.

Main Results:

• The last breast carcinoma-related death occurred 23 years post-diagnosis; 20-year overall survival was 54%, and cancer-specific survival was 81%.
• Patients with smaller tumors (pT1a-b, ≤ 10 mm) had a 20-year cancer-specific survival of 92%, compared to 75% for larger tumors (pT1c, 11-20 mm).
• None of the 48 patients with well-differentiated (Grade 1) pT1a-b tumors died of breast cancer, versus 81% survival for Grade 2-3 tumors (P=0.002).

Conclusions:

• Well-differentiated pT1a-b tumors represent a subgroup with an excellent long-term prognosis.
• A significant proportion of patients with moderately/poorly differentiated pT1a-b tumors or pT1c tumors ultimately die from breast carcinoma.
• Tumor differentiation and size are critical factors for predicting long-term outcomes in early-stage breast cancer.